Clinical Trial Update: Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. [Phase 1]

View source ↗

Summary

Phase 1 trial update of Naptumomab Estafenatox in combination with durvalumab in selected advanced or metastatic solid tumors, including esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Naptumomab Estafenatox (naptumomab estafenatox)

Snippet

Sponsor: NeoTX Therapeutics Ltd. | Conditions: ER+ Breast Cancer, Ovarian Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING